Ventiv to buy Adheris
communications services for the pharma industry, has added a new
arm to its business after agreeing to buy Adheris, a leading
provider of patient adherence programs.
The deal, worth $60 m (€50.1 m) in cash and shares, should close late in the first quarter and is expected to immediately add to >Ventiv's earnings.
">Adheris brings to Ventiv a new and valuable patient education component in the area of medication compliance - an area of increased interest to our clients," said Eran Broshy, Ventiv's CEO.
By partnering with pharmacies around the US, Adheris runs programs to build the pharmacist-patient relationship in order to encourage patients to regularly take their medication.
Medication compliance is a growing concern. Recent studies estimate that one third of US adults who have been prescribed drugs to take regularly, report that they are often or very often noncompliant with their treatment.
In addition to poor health outcomes for patients, this non-compliance means less drugs are being sold and drug companies are missing out on potential revenue. In response, they are increasingly looking at ways to try and boost medication compliance and thus sales.
"Everyone wins when adherence is improved," said Mike Evanisko, Adheris' Chairman.
"Adheris' pharmacy network, proprietary technology, and program management expertise will complement Ventiv's existing network of patient and physician services in the US," said Broshy.
Upon the close of the transaction, Adheris will become a wholly owned subsidiary of Ventiv. The Adheris brand will remain, and the company will operate under Ventiv's Communication division.
